Vimizim FDA Approval History
FDA Approved: Yes (First approved February 14, 2014)
Brand name: Vimizim
Generic name: elosufase alfa
Dosage form: Injection
Company: BioMarin Pharmaceutical Inc.
Treatment for: Mucopolysaccharidosis Type IVA
Vimizim (elosufase alfa) is an enzyme replacement therapy for patients with Mucopolysaccharidosis Type IVA (Morquio A syndrome).
Development timeline for Vimizim
| Date | Article |
|---|---|
| Feb 16, 2014 | Approval FDA Approves Vimizim to Treat Mucopolysaccharidosis Type IVA |
| Nov 20, 2013 | FDA Advisory Committee Recommends Approval of Vimizim for Morquio A Syndrome |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.